Porgaviximab Biosimilar - Research Grade

Human

Zaire Ebola virus

>1mg/ml

IgG1 - kappa

CHO Cells

Atoltivimab Biosimilar - Research Grade (ICH5362), Cosfroviximab Biosimilar - Research Grade (ICH5450), Larcaviximab Biosimilar - Research Grade (ICH5627), Maftivimab Biosimilar - Research Grade (ICH5666), Odesivimab Biosimilar - Research Grade (ICH5723)

https://www.imgt.org/mAb-DB/

ICH3002

Blue ice

A primary target for filovirus neutralization research is the Zaire ebolavirus glycoprotein. This recombinant human IgG1 kappa antibody is an unconjugated, non-therapeutic analog of porgaviximab, produced in CHO cells against Zaire Ebola virus. Supplied for research use only, it is purified to a low-endotoxin standard suitable for in vivo studies and offered in scalable milligram (mg) to gram (g) quantities for high-throughput, heavy-usage laboratories. It functions as a defined reagent for virus-neutralization assays, viral-entry studies, functional characterization, and preclinical filovirus models. The format is optimized for reproducible results across high-volume study designs.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Porgaviximab biosimilar available in bulk or gram quantities?

A: Yes — the Porgaviximab biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is research-grade Porgaviximab suitable for in vivo studies?

A: Yes, it is supplied as a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Porgaviximab biosimilar target?

A: It is an unconjugated, non-therapeutic biosimilar monoclonal antibody analogous to Porgaviximab that binds Zaire Ebola virus; for research use only (RUO).